Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

Marchica, Valentina; Franceschi, Valentina; Vescovini, Rosanna; Storti, Paola; Vicario, Emanuela; Toscani, Denise; Zorzoli, Alessia; Airoldi, Irma; Palma, Benedetta Dalla; Campanini, Nicoletta; Martella, Eugenia; Mancini, Cristina; Costa, Federica; Donofrío, Gaetano; Giuliani, Nicola

doi:10.1186/s13045-020-00919-w

Cited by 13 publications

(8 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the oncolytic effect of BVDV was increased by Bortezomib pretreatment of HMCLs. Moreover, they confirmed the oncolytic BVDV activity in an in vivo subcutaneous myeloma mouse model, which showed a reduction of tumoral burden [ 58 ].…”

Section: Direct Mechanisms Of Action Of Oncolytic Viruses In MMmentioning

confidence: 79%

See 1 more Smart Citation

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma

Marchica

Costa

Donofrío

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of bone marrow (BM) clonal plasma cells, which are strictly dependent on the microenvironment. Despite the improvement of MM survival with the use of new drugs, MM patients still relapse and become always refractory to the treatment. The development of new therapeutic strategies targeting both tumor and microenvironment cells are necessary. Oncolytic virotherapy represent a promising approach in cancer treatment due to tumor-specific oncolysis and activation of the immune system. Different types of human viruses were checked in preclinical MM models, and the use of several viruses are currently investigated in clinical trials in MM patients. More recently, the use of alternative non-human viruses has been also highlighted in preclinical studies. This strategy could avoid the antiviral immune response of the patients against human viruses due to vaccination or natural infections, which could invalid the efficiency of virotherapy approach. In this review, we explored the effects of the main oncolytic viruses, which act through both direct and indirect mechanisms targeting myeloma and microenvironment cells inducing an anti-MM response. The efficacy of the oncolytic virus-therapy in combination with other anti-MM drugs targeting the microenvironment has been also discussed.

show abstract

Section: Direct Mechanisms Of Action Of Oncolytic Viruses In MMmentioning

confidence: 79%

“…Recently, Marchica et al demonstrated the efficiency of a bovine Pestivirus , bovine viral diarrhea virus (BVDV), in killing MM cells [ 58 ]. BVDV is a single-stranded RNA virus considered one of the major viral pathogens of cattle, directly associated with mucosal disease [ 59 ].…”

Section: Direct Mechanisms Of Action Of Oncolytic Viruses In MMmentioning

confidence: 99%

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma

Marchica

Costa

Donofrío

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…BVDV is a ss-RNA virus belonging to the Flaviviridae family, and is a major viral pathogen of cattle [ 58 ]. Myeloma cell lines have been shown to express CD46, the BVDV receptor, treatment of these cells with BVDV resulted in infection and cell death by apoptosis [ 59 ]. More importantly, BVDV decreased CD138 + primary myeloma cells from patient bone marrow aspirates and did not affect CD3 + , CD19 + , or CD56 + cell populations, suggesting that the BVDV oncolytic effect was limited to CD138 + myeloma cells.…”

Section: The Use Of Oncolytic Viruses In the Treatment Of Multiple Myelomamentioning

confidence: 99%

“…In vivo, in a subcutaneous xenograft myeloma mouse model, mice were treated with BVDV intratumorally, which led to a reduction in tumour volume, and an increase in caspase-3 activity. Additionally, the authors showed pretreatment with bortezomib increased BVDV efficacy in myeloma cell lines in vitro and suggested this was due to the activation of caspase-3-meidated apoptosis [ 59 ]. Due to these limited data, there have been no clinical trials with BVDV in myeloma patients.…”

Section: The Use Of Oncolytic Viruses In the Treatment Of Multiple Myelomamentioning

confidence: 99%

The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma

Stewart

Chantry

Lawson

2021

Cancers

View full text Add to dashboard Cite

Multiple myeloma accounts for 1% of all new cancers worldwide. It is the second most common haematological malignancy and has a low five-year survival rate (53.2%). Myeloma remains an incurable disease and is caused by the growth of malignant plasma cells in the bone marrow. Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its’ analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission ‘plateau phase’ disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance. Therefore, there is a compelling clinical need for the development of novel treatment regimens to target MRD and effectively eliminate all remaining tumour cells. This review will discuss the potential use of oncolytic virus (OV) therapies in the treatment of myeloma. Specifically, it will focus on preclinical studies using DNA viruses (adenovirus (Ad), vaccinia virus (VV), myxoma virus (MYXV), and herpes simplex virus (HSV)), RNA viruses (reovirus (reo), coxsackie virus, measles virus (MV) and bovine viral diarrhoea virus (BVDV), and vesicular stomatitis virus (VSV)), and on four types of viruses (VV, reo, MV-NIS and VSV-IFNβ-NIS) that have been assessed clinically in a small number of myeloma patients.

show abstract

“…Meanwhile, the oncolytic parvovirus H-1PV has entered clinical trials targeting glioblastoma and pancreatic cancer [ 98 , 99 ]. Additionally, a nonhuman pathogen virus, bovine viral diarrhea virus (BVDV), was reported to selectively induce death in human myeloma cell lines (HMCLs), while reducing tumor growth in a mouse model by triggering apoptosis [ 100 ]. Another OV, alphavirus M1, which contains a positive-sense single-stranded RNA genome with nonstructural proteins at the 5′ end and structural proteins at the 3′ end, can inhibit the growth of gliomas, as well as hepatic, colorectal, and bladder cancers with no evidence of toxicity or serious adverse events in mice and nonhuman primates [ 101 ].…”

Section: Introductionmentioning

confidence: 99%

Oncolytic viruses for triple negative breast cancer and beyond

Jin

Wang

et al. 2021

Biomark Res

View full text Add to dashboard Cite

Biological therapy is considered an alternative treatment capable of eliciting the same effects on tumors as surgery, radiotherapy, and chemotherapy. As a major player in biological therapy, oncolytic viruses (OVs) have attracted great attention and achieved good results. Specifically, the successful application of OVs in head and neck cancer, as well as melanoma, promoted its research in triple negative breast cancer (TNBC). TNBC is a high-risk molecular type of breast cancer, characterized by strong invasion, easy recurrence, and metastasis. Due to the absence of estrogen and progesterone receptors, as well as the absence of overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2), endocrine therapy and anti HER-2 targeted therapy have proven ineffective. Although chemotherapy has shown substantial efficacy in some TNBC patients, the occurrence of drug resistance and poor prognosis have prompted the exploration of new and effective treatment methods. The emerging concept of OVs provides a new platform to treat TNBC. Indeed, several studies have confirmed the therapeutic effects of OVs in TNBC. Numerous studies have also investigated the efficacy of OVs in other malignances, including solid tumor clinical trials, thus further demonstrating the promising application of oncolytic virotherapy for TNBC. The primary focus of the current review is the examination of OV mechanisms underlying their antitumor properties, while also summarizing the ongoing progress in OV research regarding TNBC treatment, as well as the various combinatorial strategies comprising OVs and other therapies. We also briefly introduce specific relevant clinical trials and discuss some of the progress in the research of novel OVs for the treatment of other malignancies, thereby affirming the significant therapeutic potential of OVs for the treatment of TNBC, as well as other cancers.

show abstract

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

Cited by 13 publications

References 52 publications

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma

The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma

Oncolytic viruses for triple negative breast cancer and beyond

Contact Info

Product

Resources

About